Erasca (ERAS) Net Cash Flow (QoQ) (2020 - 2026)
Erasca (ERAS) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.24% |
| Mar 31, 2026 | -842.63% |
| Dec 31, 2025 | -12.53% |
| Sep 30, 2025 | 194.19% |
| Jun 30, 2025 | -258.18% |
| Mar 31, 2025 | 339.35% |
| Dec 31, 2024 | 98.90% |
| Sep 30, 2024 | -208.16% |
| Jun 30, 2024 | 687.66% |
| Mar 31, 2024 | 17.38% |
| Dec 31, 2023 | 23.68% |
| Sep 30, 2023 | 80.65% |
| Jun 30, 2023 | -1,068.91% |
| Mar 31, 2023 | -117.64% |
| Dec 31, 2022 | 182.49% |
| Sep 30, 2022 | -122.83% |
| Jun 30, 2022 | -30.21% |
| Mar 31, 2022 | 68.19% |
| Dec 31, 2021 | -129.48% |
| Sep 30, 2021 | 2,229.15% |